CAR-T Therapy Finds New Target: CD22 CAR-T Achieves 68% ORR in R/R LBCL
20/07/2024
A Phase I trial led by Stanford investigators has shown that CD22-targeted CAR-T therapy achieved an overall response rate of 68% and complete remission in 53% of patients with R/R large B-cell lymphoma relapsing after CAR19. Published in The Lancet, the study highlights CD22 as a promising new target offering hope for patients with few treatment options.